Facing the dawn of immunotherapy for hepatocellular carcinoma

Journal of Hepatology

Volumn 59, Issue 1, 2013, Pages 9-10

  Sprinzl, Martin F ^a   Galle, Peter R ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Abbreviations CTLA 4 cytotoxic T lymphocyte antigen 4 HCC hepatocellular carcinoma HCV hepatitis C virus TAA tumor associated antigen PD 1 programmed death 1 PD L1 programmed death 1 ligand

Indexed keywords

ALPHA FETOPROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 12; IPILIMUMAB; SORAFENIB; TICILIMUMAB;

ANOREXIA; CANCER PATIENT; CELL EXPANSION; CHEMOEMBOLIZATION; CYTOKINE RELEASE; DIARRHEA; DRUG EFFICACY; EDITORIAL; FATIGUE; GENE TARGETING; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIVER CELL CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RASH; SYSTEMIC THERAPY; T LYMPHOCYTE; TOXICITY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CTLA-4 ANTIGEN; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE;

EID: 84879170930     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.04.002     Document Type: Editorial

References (21)

1. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
2. J.C. Yang, M. Hughes, U. Kammula, R. Royal, R.M. Sherry, and S.L. Topalian Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J Immunother 30 2007 825 830
3. A. Ribas, R. Kefford, M.A. Marshall, C.J. Punt, J.B. Haanen, and M. Marmol Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma J Clin Oncol 31 2013 616 622
4. E. Breous, and R. Thimme Potential of immunotherapy for hepatocellular carcinoma J Hepatol 54 2011 830 834
5. A.J. Gehring, Z.Z. Ho, A.T. Tan, M.O. Aung, K.H. Lee, and K.C. Tan Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma Gastroenterology 137 2009 682 690
6. A.W. Thomson, and P.A. Knolle Antigen-presenting cell function in the tolerogenic liver environment Nat Rev Immunol 10 2010 753 766
7. J.M. Llovet, M. Ducreux, R. Lencioni, A.M. Di Bisceglie, P.R. Galle, and J.F. Dufour EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
8. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
9. Sangro B, Gomez -Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-88.
10. R. Thimme, M. Neagu, T. Boettler, C. Neumann-Haefelin, N. Kersting, and M. Geissler Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma Hepatology 48 2008 1821 1833
11. L. Ayaru, S.P. Pereira, A. Alisa, A.A. Pathan, R. Williams, and B. Davidson Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization J Immunol 178 2007 1914 1922
12. B. Weide, H. Zelba, E. Derhovanessian, A. Pflugfelder, T.K. Eigentler, and A.M. Di Giacomo Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis J Clin Oncol 30 2012 1835 1841
13. J. Yuan, M. Adamow, B.A. Ginsberg, T.S. Rasalan, E. Ritter, and H.F. Gallardo Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab Proc Natl Acad Sci U S A 108 2011 16723 16728
14. K. Hiroishi, J. Eguchi, T. Baba, T. Shimazaki, S. Ishii, and A. Hiraide Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma J Gastroenterol 45 2010 451 458
15. H.T. Jin, A.C. Anderson, W.G. Tan, E.E. West, S.J. Ha, and K. Araki Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection Proc Natl Acad Sci U S A 107 2010 14733 14738
16. S.D. Blackburn, H. Shin, W.N. Haining, T. Zou, C.J. Workman, and A. Polley Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 10 2009 29 37
17. Y. Sawada, T. Yoshikawa, D. Nobuoka, H. Shirakawa, T. Kuronuma, and Y. Motomura Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival Clin Cancer Res 18 2012 3686 3696
18. E. Mizukoshi, T. Yamashita, K. Arai, H. Sunagozaka, T. Ueda, and F. Arihara Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma Hepatology 2012 [Epub ahead of print]
19. E. Mizukoshi, Y. Nakamoto, K. Arai, T. Yamashita, A. Sakai, and Y. Sakai Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma Hepatology 53 2011 1206 1216
20. M.F. Sprinzl, F. Reisinger, A. Puschnik, M. Ringelhan, K. Ackermann, and D. Hartmann Sorafenib perpetuates cellular anti-cancer effector functions by modulating the cross talk between macrophages and natural killer cells Hepatology 2013 [Epub ahead of print]
21. R. Cabrera, M. Ararat, Y. Xu, T. Brusko, C. Wasserfall, and M.A. Atkinson Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma Cancer Immunol Immunother 2012 [Epub ahead of print]